| SPRIA | solid phase radioimmunoassay |
|---|---|
| TE | exhalation time; expiratory phase time |
| tG1 | the time required to complete the G1 phase of the cell cycle |
| tG2 | the time required to complete the G2 phase of the cell cycle |
| tM | the time required to complete the M phase of the cell cycle |
| phase-specific |
having maximum activity during a certain phase of the cell growth cycle; see under agent.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
|---|---|
| phase-specific a. |
a cytotoxic agent that has its maximum effect at a given phase of the cell growth cycle.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| phase I trial |
Clinical research protocol to establish the toxicity of a new treatment. Phase II Trial: Clinical research protocol to establish the value of a new treatment. Phase III Trial: Clinical research protocol to improve present standard therapy. Top of page
출처: www.rationaltherapeutics.com/reference/glossary.ht...
|
| phasein |
phasin.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| phaseolamin |
an α-amylase inhibitor purified from the kidney bean (Phaseolus vulgaris); it has been used in preparations alleged to enhance weight control by preventing absorption of ingested carbohydrate.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|